117697-132

Cure candidates: Characteristics of >10yr progression-free survivors (PFS-10) and continuous CR (CCR-10) after total therapy 1 and 2 (TT1, TT2) for multiple myeloma (MM).

Subcategory: 
Category: 
Lymphoma and Plasma Cell Disorders
Session Type and Session Title: 
General Poster Session, Lymphoma and Plasma Cell Disorders
Abstract Number: 

8603

Citation: 

J Clin Oncol 31, 2013 (suppl; abstr 8603)

Author(s): 

Sarah Waheed, Frits Van Rhee, Adam Rosenthal, Saad Zafar Usmani, Mian Adnan Waheed, Antje Hoering, Bart Barlogie; Myeloma Institute for Research and Therapy, Little Rock, AR; Cancer Research and Biostatistics, Seattle, WA; Texas Tech University, Odessa, TX


Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^).

Abstract Disclosures

Abstract: 

Background: Our TT studies demonstrate that long term progression free survival is achievable in MM pointing to the possible curability of MM. We report here on the base line characteristics of 33/231 TT1 patients and 109/475 TT2 patients qualifying for PFS-10, including 45/245 randomized to the control arm and 64/230 randomized to thalidomide. Methods: Baseline and response levels were compared between <10yr and >=10yr survivors and logistic regression applied to identify the critical features linked to PFS-10 status. Results: Compared to the remainder, PFS>=10yr and CCR>=10yr were characterized by lower frequencies of cytogenetic abnormalities (CA), B2M>=3.5mg/L and age >=65yr. More females and more patients with platelets >150.000/uL qualified for the >=10yr category. Finally, timely administration of 2 transplants was also over-represented in these patients. Conclusions: Long-term survival PFS-10 and CCR-10 were adversely affected by by CA and elevated B2M levels. Females more frequently attained PFS-10. Assessment of MRD by 8-color flow cytometry in these patients is in progress and will be presented at the meeting. Clinical trial information: NCT00580372, NCT 00083551.

Patient characteristics by PFS10 and CCR 10 categorization, TT1+2 patients.
Factor PFS<10 years PFS>10 years P value Not CCR at 10 years CCR at 10 years P value
Age >= 65 yr 107/601 (18%) 16/160 (10%) 0.017 111/646(17%) 12/15(10%) 0.070
Female 218/601 (36%) 74/160 (46%) 0.021 237/646(37%) 55/115(48%) 0.024
B2M >= 3.5 mg/L 232/601 (39%) 39/160 (24%) <.001 244/646(38%) 27/115(23%) 0.003
B2M > 5.5 mg/L 118/601 (20%) 18/160 (11%) 0.014 123/646(19% 13/115(11%) 0.046
Prestudy CA 210/589 (36%) 28/157 (18%) <.001 219/632(35%) 19/114(17%) <0.001
Received transplant 1 490/601(82%) 148/60(93%) <.001 526/646(91% 114/115(99%) <0.001
Received transplant 2 383/601(64%) 123/160(77%) 0.002 406/646(63%) 100/115(87%) <0.001
Logistic regression
10-year PFS
Variable N With
factor
Without
factor
OR (95% CI) P value
Multivariate Female 743 73/286 (26%) 82/457 (18%) 1.57 (1.09, 2.26) 0.0152
B2M >= 3.5 mg/L 743 37/261 (14%) 118/482 (24%) 0.58 (0.38, 0.88) 0.0107
Prestudy CA 743 28/238 (12%) 127/505 (25%) 0.44 (0.28, 0.70) 0.0004